furosemide and hypertonic saline solution — Competitive Intelligence Brief

furosemide and hypertonic saline solution (furosemide and hypertonic saline solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Loop diuretic. Area: Cardiovascular.

phase 3 Loop diuretic Na-K-2Cl cotransporter 2 Cardiovascular Small molecule

Target snapshot

furosemide and hypertonic saline solution (furosemide and hypertonic saline solution) — Aspirus Heart and Vascular Institute-Research and Education. Furosemide is a loop diuretic that works by inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb of the loop of Henle, leading to increased urine production and decreased fluid volume.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
furosemide and hypertonic saline solution TARGET	furosemide and hypertonic saline solution	Aspirus Heart and Vascular Institute-Research and Education	phase 3	Loop diuretic	Na-K-2Cl cotransporter 2
TORSEMIDE	TORSEMIDE		marketed	Loop Diuretic [EPC]	Na+/K+/2Cl- carrier system	1993-01-01
Bumex	BUMETANIDE		marketed	Loop Diuretic [EPC]	Solute carrier family 12 member 1	1983-01-01
Edecrin	ETHACRYNIC ACID	Bausch Health	marketed	Loop Diuretic [EPC]	Glutathione S-transferase P	1967-01-01
Lasix	furosemide	Generic (originally Hoechst AG)	marketed	Loop Diuretic [EPC]	ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35	1966-07-01
FUROSEMIDE	FUROSEMIDE		marketed	Loop Diuretic [EPC]		1966-01-01
Immedate Release Torsemide Tablets	Immedate Release Torsemide Tablets	Sarfez Pharmaceuticals, Inc.	marketed	Loop diuretic	Na-K-2Cl cotransporter (NKCC2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-10-06 — TORSEMIDE · 10154963 · Formulation · US
• 2034-04-03 — Lasix · 9884039 · Method of Use · US
• 2034-04-03 — Lasix · 11433044 · Method of Use · US
• 2034-04-03 — Lasix · 12370168 · Formulation · US
• 2034-04-03 — Lasix · 10272064 · Formulation · US
• 2040-12-04 — Bumex · 11123319 · Formulation · US
• 2040-12-04 — Bumex · 11260038 · Method of Use · US
• 2040-12-04 — Bumex · 12329731 · Formulation · US

Sponsor landscape (Loop diuretic class)

1. Sarfez Pharmaceuticals, Inc. · 3 drugs in this class
2. B&A Therapeutics · 1 drug in this class
3. Jose J Zaragoza, MD MSc · 1 drug in this class
4. Ferrer Internacional S.A. · 1 drug in this class
5. Heart Care Foundation · 1 drug in this class
6. Instituto de Investigación Sanitaria Aragón · 1 drug in this class
7. China National Center for Cardiovascular Diseases · 1 drug in this class
8. Lakeland Regional Health Systems, Inc. · 1 drug in this class
9. Larissa University Hospital · 1 drug in this class
10. Assistance Publique - Hôpitaux de Paris · 1 drug in this class